Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol

Therapeutic Drug Monitoring

Volumn 25, Issue 2, 2003, Pages 192-196

  Suzuki, Akihito ^a   Yasui Furukori, Norio ^a   Mihara, Kazuo ^a   Kondo, Tsuyoshi ^a   Furukori, Hanako ^a   Inoue, Yoshimasa ^b   Kaneko, Sunao ^a   Otani, Koichi ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b Mitsubishi Pharma   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

CYP2D6.; Haloperidol; Homochlorcyclizine; Promethazine; Reduced haloperidol

Indexed keywords

CYTOCHROME P450 2D6; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; HOMOCHLORCYCLIZINE; PROMETHAZINE; REDUCED HALOPERIDOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; STEADY STATE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CYCLIZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROMETHAZINE; SCHIZOPHRENIA;

EID: 0037380880     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200304000-00008     Document Type: Article

References (27)

1. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994;14:159-62.
2. Van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
3. Fang J, Baker GB, Silverstone PH, et al. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997;107:227-33.
4. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991;31: 655-60.
5. LLerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
6. LLerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
7. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997;7:415-8.
8. Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997;35:336-9.
9. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-5.
10. You YW, Kim SH, Lee MS. Coadministration of sertraline and haloperidol. Neuropsychopharmacology 1994;10:200S.
11. Babe Jr KS, Serafin WE. Histamine, bradykinin and their antagonists. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:581-600.
12. Nakamura K, Yokoi T, Inoue K, et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996;6:449-57.
13. Suzuki A. Effects of histamine H1-receptor antagonists, promethazinc and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol (in Japanese). Jpn J Clin Pharmacol Ther 1998;29:517-23.
14. American Psychiatric Association, eds. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:273-90.
15. Lingjarde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiat Scand 1987;76(suppl 334):1-100.
16. Jann MW, Lam YWF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology 1990;101:107-11.
17. Beck P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiat Scand 1986;73 (suppl 326):1-37.
18. Hikida K, Inoue Y, Miyazaki T, et al. Determination of bromperidol in serum by automated column-switching high performance liquid chromatography. J Chromatogr 1989;495:227-34.
19. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336: 529-32.
20. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
21. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995;25:193-209.
22. Meyer UA, Gut J, Kronbach T, et al. The molecular mechanism of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalyzing bufuralol and mephenytoin oxidation. Xenobiotica 1986;16:449-64.
23. Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 1999;19:149-54.
24. Daniel DG, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
25. Bowen WD, Moses EL, Tolentino PJ, et al. Metabolism of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptors. Eur J Pharmacol 1990;177:111-8.
26. Walker JM, Matsumoto RR, Bowen WD, et al. Evidence for a role of haloperidol-sensitive σ-'opiate' receptors in the motor effects of antipsychotic drugs. Neurology 1988;38:961-5.
27. Lane HY, Lin HN, Hu OYP, et al. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:299-311.